The company hopes to obtain marketing approval for its body contouring device by the end of June.
UltraShape Medical Ltd. (TASE: USLP) is targeting the Chinese market. The company has completed a safety and efficacy study of its ultrasound body contouring device in China. The company will submit the results to China's State Food and Drug Association (SFDA) for analysis at the beginning of the second quarter and expects to obtain approval of the device by the end of June.
60 patients participated in the study at medical centers in Beijing and Shanghai.
UltraShape's share price rose 7.9% today to NIS 0.04, giving a market cap of NIS 98 million.
Published by Globes [online], Israel business news - www.globes-online.com - on January 18, 2011
© Copyright of Globes Publisher Itonut (1983) Ltd. 2011